From: Novel therapies are changing treatment paradigms in metastatic prostate cancer
Trial name | Intervention | Control | DNA repair mutation required | Prior treatment for mCRPC allowed | Estimated enrollment (patients) | Trial phase | Clinicaltrials.gov identifier |
---|---|---|---|---|---|---|---|
BRCAAway | Olaparib or olaparib/AAP | AAP | Yes | No | 70 | 2 | NCT03012321 |
PROpel | Olaparib/AAP | AAP | No | No | 720 | 3 | NCT03732820 |
COMRADE | Olaparib/Ra 223 | Ra 223 | No | Yes | 112 | 1/2 | NCT03317392 |
KEYLYNK-010 | Olaparib/pembrolizumab | AAP or enzalutamide | No | Yes | 780 | 3 | NCT03834519 |
KEYNOTE-365 | Olaparib/pembrolizumab | Pembrolizumab + one of docetaxel, enzalutamide, or AAP | No | Yes | 400 | 1b/2 | NCT02861573 |
TRITON3 | Rucaparib | AAP or enzalutamide or docetaxel | Yes | No | 400 | 3 | NCT02975934 |
N/A | Rucaparib or rucaparib/nivolumab | Nivolumab | No | No | 60 | 1b/2 | NCT03572478 |
CheckMate 9KD | Rucaparib/nivolumab | Nivolumab + enzalutamide or docetaxel | No | Yes | 330 | 2 | NCT03338790 |
MAGNITUDE | Niraparib/AAP | AAP | No | No | 1000 | 3 | NCT03748641 |
TALAPRO-2 | Talazoparib/enzalutamide | Enzalutamide | No | No | 1037 | 3 | NCT03395197 |